Joshiawa Paulk

List of Publications by Year
in descending order

21	4,428	516710 16	713466 21
papers	citations	h-index	g-index

23	23	23	6324
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 2015, 348, 1376-1381.	12.6	1,244
2	The dTAG system for immediate and target-specific protein degradation. Nature Chemical Biology, 2018, 14, 431-441.	8.0	629
3	MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science, 2016, 351, 1214-1218.	12.6	396
4	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. Molecular Cell, 2017, 67, 5-18.e19.	9.7	347
5	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader. Cell Chemical Biology, 2018, 25, 88-99.e6.	5.2	313
6	Transcription control by the ENL YEATS domain in acute leukaemia. Nature, 2017, 543, 270-274.	27.8	248
7	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie - International Edition, 2017, 56, 5738-5743.	13.8	207
8	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. Nature Medicine, 2016, 22, 632-640.	30.7	176
9	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nature Chemical Biology, 2018, 14, 405-412.	8.0	176
10	Structural basis of indisulam-mediated RBM39 recruitment to DCAF15 E3 ligase complex. Nature Chemical Biology, 2020, 16, 15-23.	8.0	150
11	Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. ACS Chemical Biology, 2018, 13, 553-560.	3.4	128
12	Design and characterization of bivalent BET inhibitors. Nature Chemical Biology, 2016, 12, 1089-1096.	8.0	115
13	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. Cancer Discovery, 2016, 6, 1006-1021.	9.4	108
14	MELK is not necessary for the proliferation of basal-like breast cancer cells. ELife, 2017, 6, .	6.0	86
15	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. Science Translational Medicine, 2017, 9, .	12.4	36
16	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	10.3	26
17	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. Angewandte Chemie, 2017, 129, 5832-5837.	2.0	14
18	Lysosome-targeting chimeras evolve. Nature Chemical Biology, 2021, 17, 931-933.	8.0	14

#	Article	IF	Citations
19	A Novel Luminescence-Based High-Throughput Approach for Cellular Resolution of Protein Ubiquitination Using Tandem Ubiquitin Binding Entities (TUBEs). SLAS Discovery, 2020, 25, 350-360.	2.7	6
20	Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors. Israel Journal of Chemistry, 2017, 57, 319-330.	2.3	3
21	Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders. Blood, 2020, 136, 13-14.	1.4	0